Handling an array of matters across the life sciences and health care space, the team at Advokatfirman Lindahl KB has experience advising on licensing, capital markets issues, and broader commercial matters. Based in Uppsala, practice head Hugo Norlén provides expertise in IP matters and is frequently engaged by academic bodies. Mikael Smedeby is a key name for corporate issues.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- ‘What makes the individuals at Lindahl unique is their ability to listen, work collaboratively, and find real-world, practical solutions.'
- ‘The team at Lindahl represents a knowledgeable, skillful, practical set of lawyers who bring excellent insight and guidance to the table. They are adept at working locally and globally.’
- ‘The partners I work with are practical, experienced, knowledgeable, and timely with responses. I welcome the opportunity to work with Lindahl and frequently seek advice and counsel from many, including partners.'
- ‘Top-notch law firm. Experience and breadth in transactional work (licensing and collaborations), regulatory, litigation, and securities. Practical and wise.’
- ‘Experienced, knowledgeable and efficient.’
- ‘Excellent team led by Patrik Rindståhl. High-quality advice on various topics, fast and very supportive. ’
Key clients
- Affibody AB
- Akiram Therapeutics AB
- Alder Therapeutics AB
- Amferia AB
- AMRA Medical AB
- Antaros Medical AB
- BioArctic AB (publ)
- BioLamina AB
- Dilafor AB
- Egetis Therapeutics AB (publ)
- Intrance Medical Systems Inc
- Medivir AB (publ)
Work highlights
Advised Antaros Holding AB and its shareholders on Lauxera Capital Partners' investment.
Advised Dicot Pharma AB on its oversubscribed rights issue of units to finance the clinical phase 2a trial for the erectile dysfunction drug candidate LIB-01, including prospectus preparation and corporate documentation.
Advised Mesenkia Therapeutics AB on a worldwide exclusive license agreement with University of Tokyo, Yamaguchi University, and RIKEN for proprietary technology to develop novel therapeutic agents targeting glioblastoma brain tumours.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Hugo Norlén
Other key lawyers
Mikael Smedeby; Patrik Rindståhl